Interim analysis from the ASSURE trial shows that seladelpar significantly improves liver stiffness in patients with primary biliary cholangitis (PBC). This finding supports the potential of seladelpar as a therapeutic option for this rare liver disease.
seladelpar improves liver stiffness in pbc assure interim analysis
Original title: “Seladelpar improves liver stiffness in PBC: ASSURE interim analysis.”